Yahoo Finance3y
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...
pharmaphorum2d
Digital therapeutics at a turning point: What we heard at DTx East
This year the digital therapeutics space took a hit with the downfall of Pear Therapeutics, one of the most well-known of the industry’s still-active pioneers. Combined with Akili Interactive ...
VentureBeat1mon
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines
Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their merger to create an entirely new chapter in ophthalmic ...
Nature3mon
A turning point for ADCs
Harnessing new technology to produce next-generation ADCs Torres was working as an entrepreneur in residence at the Texas Medical Center Innovation’s Accelerator for Cancer Therapeutics—a ...
Business Wire1mon
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines
LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their ...